Dr Reddy’s receives EU nod for AVT03 biosimilar denosumab
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
Winlevi is authorized in EU for the treatment of acne vulgaris
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
The 2025 edition of the EdelGive Hurun list recognizes 24 exceptional women leaders for their philanthropic impact across critical areas
The X CUBE 50 integrates ALPINION’s advanced X+ Architecture
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
Subscribe To Our Newsletter & Stay Updated